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Abstract: Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a 
new analog of the active form of vitamin D. Eldecalcitol has recently been approved for the 
treatment of osteoporosis in Japan. In addition to regulation of calcium metabolism carried out 
by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone 
resorption and causes a significant increase in bone mineral density. A Phase III clinical trial on 
osteoporosis showed that eldecalcitol reduced the incidence of new vertebral fractures over 3 years 
by 26% compared with alfacalcidol. Although the overall risk of nonvertebral fractures was not 
reduced by eldecalcitol, the risk of wrist fracture was decreased significantly in the eldecalcitol 
group (71%) compared with the alfacalcidol group. The serum level of 25-hydroxyvitamin D 
(25[OH]D) was normalized by supplementation of native vitamin D in this trial, so the desirable 
effects on bone by eldecalcitol were considered to be derived from its distinctive pharmacological 
action. Increased blood calcium was observed in 21% of patients treated with eldecalcitol, and 
hypercalcemia (.11.5 mg/dL) occurred in 0.4% of eldecalcitol recipients, so serum calcium 
concentration should be monitored after starting eldecalcitol treatment. Eldecalcitol has dual 
effects on the metabolism of bone and calcium and is useful for the treatment of osteoporosis, 
especially for elderly patients (who frequently suffer from vitamin D deficiency). This article 
reviews the clinical efficacy and safety of eldecalcitol in the treatment of osteoporosis.
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Introduction
Osteoporosis is a systemic skeletal disease associated with low bone mass and micro-
architectural deterioration of bone tissue, with a consequent increase in bone fragility 
and fracture risk.1 Osteoporosis-related fractures occur commonly in the spine, hip and 
distal radius. These fractures impact negatively on quality of life and increase morbid-
ity and mortality.2,3 Treatment of osteoporosis is important for preventing osteoporotic 
fractures and reducing the health care burden.
Vitamin D is a crucial factor for the intestinal absorption of calcium to maintain 
bone strength. A deficiency in vitamin D causes impaired absorption of calcium and 
bone mineralization, leading to rickets in children and osteomalacia in adults.4–6 The 
elderly are at risk of a deficiency and an insufficiency of vitamin D because of their 
reduced mobility and consequent decreased exposure to sunshine, a low food intake, 
and decline in renal function.4,7 Vitamin D insufficiency causes greater secretion of 
parathyroid hormone (PTH) due to the low serum levels of calcium and active vitamin 
D, resulting in high bone turnover and increased bone resorption. Vitamin D insuffi-
ciency is also associated with muscle weakness, leading to an increased risk of falling.8,9 Clinical Interventions in Aging 2013:8 submit your manuscript | www.dovepress.com
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These detrimental effects may contribute to osteoporosis and 
increased fracture risk in patients with a deficiency and an 
insufficiency of vitamin D.10
Clinical trials have suggested that the active form of 
vitamin D reduces the risk of fractures and falls.11–13 A new 
analog of vitamin D, eldecalcitol, has recently been approved 
for the treatment of osteoporosis in Japan. Eldecalcitol 
has strong effects on the reduction of bone resorption and 
increase in bone mineral density (BMD) in addition to the 
effects on calcium metabolism retained by conventional 
vitamin D analogs.14,15
Vitamin D
Metabolism and action
Vitamin D is one of the lipid-soluble hormones produced 
in the skin through ultraviolet irradiation of 7-dehydroc-
holesterol. Vitamin D is also obtained from animal-based 
(vitamin D3) or plant-based (vitamin D2) foods.10,16 In the 
human body, vitamin D is hydroxylated in the liver to 
25-hydroxyvitamin D (25[OH]D) and subsequently in the 
kidney to its biologically active form: 1,25-dihydroxyvitamin D 
(1,25[OH]2D) (Figure 1).16,17 In the circulation, these vita-
min D metabolites (25[OH]D and 1,25[OH]2D) are bound 
to vitamin D-binding protein (DBP). The active metabolite 
1,25(OH)2D enters the cell and binds to the vitamin D recep-
tor (VDR), which belongs to the nuclear receptor superfamily. 
This ligand-bound VDR forms a heterodimer with the retin-
oid X receptor (RXR). The VDR/RXR complex binds to the 
vitamin D-responsive element on a target gene to regulate its 
transcription. Vitamin D regulates serum concentrations of 
calcium and phosphate by increasing intestinal absorption 
of calcium and phosphate, promoting renal reabsorption of 
calcium, and stimulating bone resorption.16,18
Vitamin D deficiency and osteoporosis
The serum level of 25(OH)D is the best indicator of 
vitamin D status.19,20 Vitamin D deficiency is defined 
as a 25(OH)D level ,20  ng/mL  (50  nmol/L)  and 
vitamin D insufficiency as a 25(OH)D level of 21–29 ng/mL 
(52.5–72.5 nmol/L).4,20 Deficiency/insufficiency of vitamin D 
is very common in elderly people due to their low intake of 
vitamin D, decreased exposure to sunlight, and impaired renal 
function. More than one-half of postmenopausal women have 
a 25(OH)D level ,30 ng/mL.21,22
Severe vitamin D deficiency can cause rickets in children 
and osteomalacia in adults, characterized by impaired bone 
mineralization.9,10 Conversely, deficiency/insufficiency of 
vitamin D causes a decrease in the serum concentration of 
calcium due to a reduction in intestinal absorption of   calcium. 
This hypocalcemia stimulates PTH secretion (secondary 
hyperparathyroidism), resulting in an increase in bone 
resorption and decrease of BMD. This may contribute to the 
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pathogenesis of osteoporosis.19,20 Vitamin D deficiency is also 
associated with muscle weakness, leading to an increased risk 
of falling and fractures.8,9 A significant correlation between 
the serum concentration of 25(OH)D and falls in elderly 
people has been reported.23–25
Active form of vitamin D  
for the treatment of osteoporosis
The active form of vitamin D (1α,25-dihydroxyvitamin D3, 
  calcitriol) and its prodrug (1α-hydroxyvitamin D3,   alfacalcidol) 
have been approved for the treatment of osteoporosis in Japan 
(Figure 1).26 Both calcitriol and alfacalcidol showed a modest 
increase in BMD,27,28 and reduced the risk of vertebral and 
nonvertebral fractures.11,12,29 The number of falls were also 
reduced by treatment with active vitamin D analogs.13,28–30 
Meta-analyses suggest that the vitamin D analogs   (alfacalcidol 
and calcitriol) are more effective in preventing bone loss, 
fractures, and falls compared with native vitamin D.12,31
Eldecalcitol
Eldecalcitol: a new, active vitamin D analog
Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] 
vitamin D3, ED-71) has a hydroxypropyloxy group at 
the 2β-position of 1,25(OH)2D3, which has been isolated 
from .900 vitamin D analogs, based on the activity that 
stimulated BMD in vivo (Figure 1).14,15,32,33 Compared with 
1,25(OH)2D3, eldecalcitol has a higher affinity for serum 
DBP, binds more weakly to VDR, and shows lower potency in 
suppression of serum PTH (Table 1).32–35 The plasma half-life 
of eldecalcitol is longer than that of 1,25(OH)2D3, probably 
due to the higher affinity for DBP.
Preclinical studies
In ovariectomized (OVX) animal models of osteoporosis, 
eldecalcitol suppressed osteoclastic bone resorption and 
increased BMD to a greater extent than alfacalcidol. There 
was no significant difference in calcium absorption and serum 
PTH suppression between eldecalcitol and alfacalcidol, so the 
effect of increasing BMD by eldecalcitol seems to be inde-
pendent of calcium metabolism.36 Eldecalcitol also prevented 
glucocorticoid-induced alterations in bone metabolism by 
increasing intestinal absorption of calcium, reducing osteo-
clastic bone resorption, and enhancing mineralization in rats.37 
Histological and histomorphological analyses revealed that 
eldecalcitol and alfacalcidol reduced osteoclast numbers and 
diminished osteoclastic activity/function without promoting 
osteoclast apoptosis in OVX rats.36,38 It has been shown that 
administration of eldecalcitol preferentially suppressed the 
expression of receptor activator of nuclear factor kappa B 
ligand (RANKL) in osteoblast-lineage cells around the tra-
becular bone compared with 1,25(OH)2D3.39 Eldecalcitol and 
alfacalcidol dose-dependently stimulated focal bone formation 
that started without prior bone resorption (bone minimodel-
ing).40,41 Reduction of bone resorption and stimulation of focal 
bone formation were more clearly observed in eldecalcitol-
treated rats than in 1,25(OH)2D3-treated rats.39,41
Combination treatment  
of eldecalcitol with alendronate  
or raloxifene in OVX rats
In OVX rats, the combination of alendronate and eldecalcitol 
improved the mechanical properties of the lumbar spine and 
mid-shaft femur by additive suppression of bone resorption 
while maintaining bone formation, which was more benefi-
cial than monotherapy with alendronate or eldecalcitol.42 
The combination of alendronate and eldecalcitol had a more 
beneficial antiosteoporotic effect by inhibiting osteoclastic 
bone resorption and maintaining osteoblastic function, 
compared with combination treatment with alendronate and 
alfacalcidol.43 Combination treatment with eldecalcitol and 
raloxifene improved bone mechanical strength in OVX rats 
more than either type of monotherapy by increasing BMD 
and suppressing bone turnover.44
Clinical studies
Pharmacokinetics and pharmacology
A single dose of eldecalcitol (0.75 µg) was administered to 32 
healthy men while fasting. The vitamin D analog was absorbed 
rapidly and eliminated gradually from serum, with a mean 
time to maximum drug concentration (Tmax) of ~3.4 hours 
and a mean half-life (t1/2) of ~53 hours.45 The time courses of 
serum eldecalcitol concentrations with administration while 
fasting and after a meal were similar. With multiple dosing, 
the serum eldecalcitol concentration reached steady state by 
Table 1 Biological evaluation of eldecalcitol
Characteristics 1,25(OH)2D3 Eldecalcitol
Affinity to vitamin D receptors 100 44.6
Affinity to vitamin D-binding protein 100 422
Inhibition of parathyroid hormone  
secretion
100 3.54
Note:  Each  value  of  eldecalcitol  represents  the  percentage  relative  to  that  of 
1.25(OH)2D3.
Adapted from J Steroid Biochem Mol Biol, 103(3–5), Hatakeyama S, Nagashima S, Imai N, 
et al, Synthesis and biologi  cal evaluation of a 3-positon epimer of 1alpha, 25-dihydroxy-
2beta-(3-hydroxypropoxy)  vitamin  D3  (ED-71),  222–226,  Copyright  (2007),  with 
permission from Elsevier.34
Abbreviation: 1,25(OH)2D3, 1,25-dihydroxyvitamin D3.Clinical Interventions in Aging 2013:8 submit your manuscript | www.dovepress.com
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13 days after the first dose. The pharmacokinetics of eldecal-
citol were linear in the dose range 0.1–1.0 µg.45
To compare the effects of eldecalcitol and alfacalcidol 
on the metabolism of bone and calcium, a randomized open-
label clinical trial was conducted in 59 post-menopausal 
women. Eldecalcitol could effectively inhibit bone resorption 
more strongly than alfacalcidol with a similar effect on bone 
formation and a comparable effect on urinary excretion of 
calcium.46
Phase II studies
In an early Phase II clinical trial, a randomized controlled study 
with eldecalcitol was conducted with 109 osteoporotic sub-
jects. The patients were assigned randomly to 0.25, 0.5, 0.75, 
or 1.0 µg/day of eldecalcitol administered via the oral route for 
6 months. Eldecalcitol increased lumbar BMD in a dose-depen-
dent manner without causing hypercalcemia or hypercalciuria. 
Eldecalcitol also exhibited a dose-dependent suppression of a 
bone resorption marker (urinary   deoxypyridinoline) without 
a significant reduction in osteocalcin.47,48
Many patients have serum 25(OH)D levels ,20 ng/mL. 
Hence, the effect of eldecalcitol on bone mass might be influ-
enced by vitamin D insufficiency and could merely reflect a 
nutritional supplementary effect of vitamin D insufficiency. 
To solve this problem, a randomized, double-blind, placebo-
controlled clinical trial was conducted with 219 osteoporotic 
patients under vitamin D supplementation (200 or 400 IU/day). 
Subjects were assigned randomly to receive 0.5, 0.75, or 
1.0 µg/day of eldecalcitol for 12 months. After treatment 
with eldecalcitol for 12 months, lumbar spine BMD increased 
from baseline by 2.2%, 2.6%, and 3.1% in the 0.5, 0.75, and 
1.0 µg eldecalcitol groups, respectively; whereas, lumbar 
spine BMD decreased by 0.7% in the placebo group. Total 
hip BMD also increased with 0.75 and 1.0 µg eldecalcitol 
from baseline by 0.6% and 0.9%, respectively. Conversely, 
in the placebo and 0.5 µg eldecalcitol group, total hip BMD 
decreased slightly from baseline (−0.9% and −0.8%). Markers 
of bone formation and resorption were suppressed by ≈20% 
after 12 months of treatment with 0.75 and 1.0 µg eldecalci-
tol. Transient increase in serum calcium level .10.4 mg/dL 
(.2.6 mmol/L) occurred in 7%, 5%, and 23% of subjects in 
the 0.5, 0.75, and 1.0 µg eldecalcitol groups, respectively; but 
none of them developed sustained hypercalcemia.49 Post hoc 
analyses of the trial revealed that eldecalcitol could increase 
lumbar and hip BMD in osteoporotic patients, regardless of 
their vitamin D status.50 These results suggest that eldecalcitol 
can exert its effect on bone independently of the nutritional 
supplementation with native vitamin D.
Phase III studies
Based on the results of Phase II clinical studies, a 3-year, 
randomized, double-blind, active comparator, superiority 
trial was carried out to compare the effect of eldecalcitol 
(0.75 µg/day) with that of alfacalcidol (1 µg/day) in pre-
venting fractures in patients with osteoporosis.51 A total of 
1,054 patients aged 46–92 years (mean, 72.1 years) were 
assigned randomly to receive eldecalcitol (n = 528) or 
alfacalcidol (n = 526). Patients with low serum levels of 
25(OH)D (,20 ng/mL) were supplemented with 400 IU/day 
of vitamin D3. Compared with the alfacalcidol group, the 
incidence of vertebral fractures was lower in the eldecalcitol 
group after 36 months of treatment (13.4% versus 17.5%) 
with a relative risk reduction of 26% (P = 0.092; hazard 
ratio [HR] 0.74; 90% confidence interval [CI]: 0.56–0.97) 
(Figure 2). The incidence of new vertebral fractures was 
not different between the two groups during the first year, 
but was significantly lower in the eldecalcitol group during 
the third year (3.9% versus 7.0%, odds ratio [OR] 0.51, 
P = 0.037; 95% CI 0.27–0.97). With regard to the total 
number of nonvertebral fractures at 36 months, no signifi-
cant difference was observed between the eldecalcitol and 
alfacalcidol groups (8.0% versus 9.5%, HR 0.85, 95% CI 
0.55–1.31). However, eldecalcitol reduced the incidence 
of three major nonvertebral fractures (humerus, wrist, hip) 
compared with alfacalcidol (2.5% versus 4.9%, HR 0.51, 
95% CI 0.25–1.03), which was due, in particular, to a 
marked decrease in the incidence of wrist fractures (1.1% 
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versus 3.6%, HR 0.29, 95% CI 0.11–0.77, P = 0.009) 
 ( Figure 3). Eldecalcitol increased lumbar and hip BMD 
more strongly than alfacalcidol (Figures 4A and B). Levels 
of bone turnover markers (bone-specific alkaline phos-
phatase [BSAP] and urinary crosslinked N-telopeptide of 
type-I bone collagen [NTX]) were significantly lower with 
eldecalcitol than with alfacalcidol (Figures 4C and D). The 
decrease from baseline in bone turnover markers after the 
eldecalcitol treatment exceeded the minimum significant 
change, authorized by the Japan Osteoporosis Society.52 
These results suggest that eldecalcitol is more efficacious 
than alfacalcidol in preventing vertebral and wrist fractures 
in osteoporotic patients.51
Among the adverse events, the prevalence of an increase 
in serum and urinary levels of calcium was higher in the 
eldecalcitol group compared with the alfacalcidol group 
(Table 2). Increased serum calcium was observed in 21.0% 
of eldecalcitol recipients and 13.5% of alfacalcidol recipients, 
while hypercalcemia developed in two patients (0.4%) in the 
eldecalcitol group but none in the alfacalcidol group. There 
was no significant difference in the prevalence of urolithiasis 
and in the estimated glomerular filtration rate between the 
two groups.51
Post hoc analyses  
of the Phase III study
Post hoc analyses of the Phase III study revealed that the inci-
dence of vertebral fracture at the lower spine was lower in the 
eldecalcitol group than in the alfacalcidol group (P = 0.029). 
The incidence of severe vertebral fractures (grade III) was 
lower in the eldecalcitol group than in the alfacalcidol group 
(3.8% versus 6.7%; HR, 0.53; 95% CI, 0.29–0.96; P = 0.036). 
Eldecalcitol and alfacalcidol improved health-related qual-
ity of life (HRQoL) scores, but overall improvement from 
the baseline of HRQoL scores was observed clearly in the 
eldecalcitol group.53
Eldecalcitol reduced the incidence of osteoporotic fractures, 
as defined by the World Health Organization, more than alfa-
calcidol (18.6% versus 25.2%; HR, 0.70; 90% CI, 0.54–0.93; 
P = 0.013) and decreased the risk of major osteoporotic frac-
tures included in the Fracture Risk Assessment Tool (FRAX)54 
(11.1% versus 16.3%; HR, 0.66; 95% CI, 0.46–0.94; P = 0.020). 
A significant decrease in the incidence of nonvertebral fractures 
was also observed in the eldecalcitol group.55
To ascertain if eldecalcitol can cause severely suppressed 
bone turnover, post hoc analyses of the Phase III trial about 
the changes in bone turnover markers after   eldecalcitol 
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treatment in osteoporotic patients were undertaken. 
Eldecalcitol reduced markers of bone turnover rapidly and 
kept them within the normal range. In patients whose base-
line values for bone turnover markers were low, eldecalcitol 
treatment did not reduce the bone turnover markers further 
during a 3-year treatment period.56
The effects of eldecalcitol on bone geometry and the 
biomechanical properties of the proximal femur were 
investigated by computed tomography in a subgroup of 
the Phase III study (n = 193). Longitudinal analyses of hip 
geometry revealed the advantages of eldecalcitol over alfa-
calcidol in: increased cortical cross-sectional area;   volumetric 
BMD of the neck and shaft of the femur; bone mass; and 
  maintenance of cortical thickness (probably through mitigat-
ing   endocortical bone resorption). By improving the biome-
chanical properties of the proximal femur, eldecalcitol could 
reduce the risk of hip fracture.57
Place of eldecalcitol  
in the treatment of osteoporosis
The vitamin D analogs alfacalcidol and calcitriol have been 
used for the treatment of osteoporosis in Japan. However, 
these drugs are not used as first-line therapy for osteoporosis, 
because they have weaker inhibitory effects on fractures than 
bisphosphonates, selective estrogen receptor modulators, or 
teriparatide. The new active form of vitamin D, eldecalcitol, 
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has stronger effects on the inhibition of bone resorption, 
increases BMD, and prevents osteoporotic fractures compared 
with alfacalcidol. It has been reported that native and active 
vitamin D reduced the risk of falling among older individu-
als.13 There are no data regarding the efficacy of eldecalcitol 
for preventing falls, but marked inhibition of wrist fractures by 
eldecalcitol may be explained (at least in part) by the preven-
tive effects of the drug on falling. Moreover, it has recently 
been noted that low serum levels of vitamin D are associated 
with several adverse outcomes in the musculoskeletal, innate 
immune, and cardiovascular systems; and they are also associ-
ated with increased all-cause mortality.19,20 Eldecalcitol has 
effects on the metabolism of bone and calcium and may pre-
vent falling, so multiple improvements in patients with osteo-
porosis can be expected with only one drug, which may lead 
to a reduction in the health care burden. Eldecalcitol would 
be preferable, especially for elderly people with osteoporosis, 
because of the high prevalence of vitamin D deficiency. It 
has recently been indicated that children, young adults, and 
middle-age adults are at an equally high risk for vitamin D 
deficiency/insufficiency,4,20 so osteoporosis in young people 
may also be a target for treatment with eldecalcitol.
In preclinical studies using OVX rats, favorable results 
have been obtained upon combination treatment of eldecalci-
tol with alendronate or raloxifene. Clinical studies have indi-
cated the advantages of combination therapy with   alfacalcidol 
and alendronate for the prevention of osteoporosis-related 
fractures.58,59 In the post hoc analyses of the Phase III trial, 
eldecalcitol normalized and did not overly suppress bone turn-
over – even in patients with low pretreatment levels of bone 
turnover markers.56 These results may raise expectation of 
combined therapy with eldecalcitol and antiresorptive agents; 
however, clinical data for the combined therapy – including 
eldecalcitol – have not been available to date. Future clinical 
studies regarding the combination treatment of eldecalcitol 
with other drugs for osteoporosis are required.
The precise pharmacological action of the active form of 
vitamin D on bone metabolism is not fully understood. It has 
been shown that c-Fos and RANKL may be the targets of the 
action of vitamin D.39,60 Although eldecalcitol and 1,25(OH)2D3 
are known to enhance RANKL expression in vitro, eldecalcitol 
suppresses the expression of RANKL in osteoblast-lineage 
cells and reduces the bone resorption in vivo.39,40 This discrep-
ancy between in vitro and in vivo studies has not been fully 
explained. Recent histological analyses in OVX rats revealed 
that the preosteoblastic layer, with which osteoclastic precur-
sors interact for mutual differentiation, was poorly developed 
in eldecalcitol-treated rats.40 Eldecalcitol also promoted focal 
bone formation, known as bone minimodeling, which is inde-
pendent of bone resorption. The increased macrophage number 
and the decreased osteoclast number in the bone marrow of 
eldecalcitol-treated rats were also observed.40 It has also been 
reported that RANKL was expressed preferentially by imma-
ture osteoblasts, and the expression level decreased during 
their maturation.61 Based on these results, eldecalcitol may 
force osteoblast maturation and prevent cell-to-cell interaction 
between preosteoblasts and osteoclastic precursors, leading to 
lower osteoclast number and decreased bone resorption.
Table 2 Incidence of adverse events
Event Eldecalcitol 
(N = 528)
Alfacalcidol 
(N = 526)
Risk 
ratio
95% 
confidence 
interval
General
Any adverse events 520 (98.5%) 518 (98.5%) 1.00 0.99–1.02
Nasopharyngitis 332 (62.9%) 312 (59.3%) 1.06 0.96–1.17
Contusion 119 (22.5%) 118 (22.4%) 1.00 0.80–1.26
Urine calcium  
increased
135 (25.6%) 82 (15.6%) 1.64 1.28–2.10
Blood calcium  
increased
111 (21.0%) 71 (13.5%) 1.56 1.19–2.04
Back pain 72 (13.6%) 81 (15.4%) 0.89 0.66–1.19
Osteoarthritis 82 (15.5%) 70 (13.3%) 1.17 0.87–1.57
Arthralgia 54 (10.2%) 52 (9.9%) 1.03 0.72–1.48
Eczema 54 (10.2%) 50 (9.5%) 1.08 0.75–1.55
Constipation 39 (7.4%) 58 (11.0%) 0.67 0.45–0.99
Headache 51 (9.7%) 39 (7.4%) 1.30 0.87–1.94
Diarrhea 50 (9.5%) 38 (7.2%) 1.31 0.88–1.96
Gastroenteritis 46 (8.7%) 41 (7.8%) 1.12 0.75–1.67
Periarthritis 45 (8.5%) 41 (7.8%) 1.09 0.73–1.64
Spinal fracture 38 (7.2%) 46 (8.7%) 0.82 0.54–1.24
Cystitis 36 (6.8%) 44 (8.4%) 0.82 0.53–1.24
Hypertension 41 (7.8%) 36 (6.8%) 1.13 0.74–1.75
Gastritis 34 (6.4%) 40 (7.6%) 0.85 0.54–1.32
Pain in extremity 31 (5.9%) 40 (7.6%) 0.77 0.49–1.21
Stomatitis 37 (7.0%) 32 (6.1%) 1.15 0.73–1.82
Dermatitis contact 38 (7.2%) 28 (5.3%) 1.35 0.84–2.17
Insomnia 34 (6.4%) 32 (6.1%) 1.06 0.66–1.69
Dizziness 29 (5.5%) 32 (6.1%) 0.90 0.55–1.47
Cataract 32 (6.1%) 27 (5.1%) 1.18 0.72–1.94
Joint sprain 29 (5.5%) 28 (5.3%) 1.03 0.62–1.71
Spinal osteoarthritis 23 (4.4%) 34 (6.5%) 0.67 0.40–1.13
Stomach discomfort 27 (5.1%) 25 (4.8%) 1.08 0.63–1.83
Exanthem 15 (2.8%) 33 (6.3%) 0.45 0.25–0.82
Serious adverse  
events
110 (20.8%) 134 (25.5%) 0.82 0.66–1.02
Death 4 (0.8%) 6 (1.1%) 0.66 0.19–2.34
Cancer 11 (2.1%) 16 (3.0%) 0.68 0.32–1.46
Discontinued due to 
adverse events
31 (5.9%) 40 (7.6%) 0.77 0.49–1.21
Calcium-related adverse events
Urolithiasis 7 (1.3%) 5 (1.0%) 1.39 0.45–4.37
Note: Adapted from Matsumoto T, Ito M, Hayashi Y, et al. A new active vitamin D3 analog, 
eldecalcitol, prevents the risk of osteoporotic fractures – a randomized, active comparator, 
double-blind study. Bone. 2011;49(4):605–612, with permission from Elsevier.51Clinical Interventions in Aging 2013:8 submit your manuscript | www.dovepress.com
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A recent study revealed that the active form of vitamin D, 
including eldecalcitol, significantly suppressed the   expression 
of bone tropic S1PR2 in circulating osteoclast precursor 
monocytes. As a result, mobilization of the osteoclast pre-
cursor monocytes from the bone to the blood was enhanced, 
causing a suppression of bone resorption.62
Conclusion
Eldecalcitol possesses a strong inhibitory effect on bone 
resorption and causes a significant increase in BMD. Phase III 
clinical trials revealed that the incidence of vertebral and wrist 
fractures was significantly reduced in the eldecalcitol group 
compared with the alfacalcidol group. To date, eldecalcitol 
is not available outside of Japan. Therefore, all clinical trials 
have been conducted in Japan. This unique vitamin D analog is 
thought to be useful, especially for patients with osteoporosis 
and vitamin D deficiency. Approval of the drug for osteopo-
rosis treatment in other countries is expected. Increases in 
blood and urinary levels of calcium were the most frequent 
adverse events in the treatment with eldecalcitol, though 
hypercalcemia was observed in only a few patients. Blood 
and urinary calcium should be monitored during eldecalcitol 
treatment. Large-scale clinical trials that compare the effects 
of eldecalcitol with other drugs for osteoporosis, as well as 
evaluation of combination therapy, should be carried out.
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